Drug combo is the first to prolong ketamine’s antisuicide effects
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Oct-2026 22:16 ET (31-Oct-2026 02:16 GMT/UTC)
New research published online today in the American Journal of Psychiatry finds that low-dose buprenorphine, given after a single ketamine infusion, significantly sustained reductions in suicidal ideation in adults with major depressive disorder. The randomized, double-blind, placebo-controlled trial is the first to show that a pharmacologic intervention may help maintain and build on ketamine’s anti-suicidal effects in this at-risk population.
A new study led by Curtin University has revealed millions of dementia cases across the Western Pacific Region could potentially be prevented by implementing country-specific strategies to address key risk factors such as education access, obesity and mental health.
A new study from Reichman University, published in the prestigious journal JAMA Network Open, has found that an AI-based conversational support platform can significantly reduce symptoms of anxiety and depression, form a meaningful therapeutic alliance with users, and provide round-the-clock emotional support.